Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: * Share my experience on the benefits that bipolar radiofrequency offers us with the combination of dissimilar handpieces (including fractional and/or RFAL technology) in the non-surgical treatment of entities at the genital level such as hypertrophy of the labia minora and ptosis of the labia majora. , in the clitoral hood, in pelvic floor dysfunctions such as stress urinary incontinence, certain degrees of prolapse, urogenital atrophy.
*Show the before and after results clinically and the changes in the tissue under ultrasound vision in real time through elastography.

Introduction: For more than 50 years in medicine, radiofrequency has been applied for different treatments, however, its application to the female external genitalia has only emerged in the last decade. The use of radiofrequency in this region is of particular interest since the tensor effect at tissue level is known. Lordella et al , Vanaman et al, used radiofrequency in patients with vulvovaginal hyperlaxity with a high rate of post-treatment satisfaction and improvement in sexual function (lubrication and arousal).

Materials / method: Bipolar radiofrequency machine with different devices that we use in synergies. Whether fractionated, RFAL method and non-invasive to achieve improvement in genital, pelvic floor and abdominal CORE disorders in women.
I shall present 10 exemplary clinical cases of how these devices can be combined for a better result.
One ultrasound machine to measure changes in the tissue in real time after treatment.
I will show you videos and published studies with this type of energy that is revolutionizing our surgical practice.

Results: -All clinical cases (100%) shown felt satisfied with their evolution after completing the therapies.
-Improvement in the measurement of the vaginal maturity index, sexual health, EVA and ICQSF scale.
-Sonographically we demonstrate the results of the improvement in the tissues with elastography and flow doppler (virtual biopsy (r))

Conclusion: The most important point: the learning curve of these techniques for professionals is not long, it is safe and benefits for our patients.

We empower sexual and social health of many women, by not submitting them to surgery at the outset, with the added risks and slow recovery.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: To demonstrate the safety and effectiveness of a vaginal erbium laser treatment for GSM (smooth Hyperstack plus previous hydration of the vaginal mucosa with injectable 20 mg cross-linked HA), in patients with poor or no response to the classic protocol of Smooth Mode erbium laser.

Introduction: Treatment of Genitourinary Syndrome of Menopause (GSM) with energy-based devices has a non-small percentage of failure and undesirable effects due to the lack of the main chromophore, amount of water in the aging vaginal mucosa.

Materials / method: 21 patients that presented typical symptoms of vaginal atrophy (GSM) during the post-menopausal period and who did not have a satisfactory response to the standard laser protocol (non-ablative erbium) were recruited to participate in this prospective study conducted between September 2022 and October 2023. Patients had a mean age of 70 years with an average BMI of 25.18. All participants were first treated with a single application of 1 ml of injectable reticulated hyaluronic acid (20 mg) to increase the amount of water in tissue (the laser chromophore), after previously applying topical lido

Results: 21 patients completed the three-month FU, while 19 completed the six-month FU. Four parameters were evaluated at the FU visits:
a) Intercourse pain level using VAS.
b) Gloria Bachmann’s Vaginal Health Index (VHI).
c) Vaginal cytology (Maturation value and Maturation index). .
d) Vaginal pH.
No complications or adverse effects were recorded in relation to the procedure.
We showed statistically significant improvements in the trophism of the vagina and related symptoms in all parameters evaluated at three- and six-months FU for all treated patients.

Conclusion: Following a global evolution towards minimally invasive procedures, results of this study are showing that non-ablative Er:YAG laser in a hyperstack technique with the combination of injectable 20 mg of a cross-link hyaluronic acid in non-responder postmenopausal patients, is safe and effective and can provide better outcomes, avoiding undesirable complications that are possible in elderly women.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability